Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18012836 | 0.92 | SUCNR1 (0.49) | SUCNR1DRD2ACACBACACACYP3A4 | |
| SCHEMBL28446331 | 0.91 | SUCNR1 (0.48) | SUCNR1DRD2ACACBACACACYP3A4 | |
| Lithium Ion SCHEMBL17966543 | 0.90 | SUCNR1 (0.46) | SUCNR1DRD2ACACBACACACYP3A4 | |
| SCHEMBL17966540 | 0.89 | SUCNR1 (0.40) | SUCNR1DRD2ACACBACACAPDPK1 | |
| SCHEMBL30875448 | 0.88 | DRD2 (0.43) | SUCNR1DRD2ACACBACACACYP3A4 | |
| SCHEMBL17998113 | 0.88 | DRD2 (0.43) | SUCNR1DRD2ACACBACACACYP3A4 | |
| SCHEMBL18013523 | 0.85 | IRAK4 (0.53) | SUCNR1 | |
| SCHEMBL19407199 | 0.85 | DRD2 (0.42) | SUCNR1DRD2ACACBACACACYP3A4 | |
| SCHEMBL17998124 | 0.83 | PDPK1 (0.46) | DRD2ACACBACACACYP3A4CACNA1G | |
| SCHEMBL17966533 | 0.82 | IRAK4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253764-B1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-06-09 | — | — | EP | disclosed |
| EP-3253764-B1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-06-09 | — | — | EP | disclosed |
| CN-107849055-B | Macrocyclic compounds useful as IRAK1/4 inhibitors and uses thereof | 默克专利有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-9815836-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-9815836-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-9815836-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20170275284-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275284-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275284-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-9708324-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9708324-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9708324-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| WO-2016127025-A1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016127025-A1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| US-20160229856-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229856-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229856-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229856-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | IRAK4, IRAK1, IRAK2 | SUCNR1 1360/4885DRD2 4829/4885ACACB 1676/4885 |
| US-20170275284-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | IRAK4, IRAK1, IRAK2 | SUCNR1 1360/4885DRD2 4829/4885ACACB 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.